How were Aradigm's earnings last quarter?

Aradigm Co. (NASDAQ:ARDM) released its quarterly earnings data on Thursday, November, 15th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.03. The firm had revenue of $0.28 million for the quarter.

What other stocks do shareholders of Aradigm own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aradigm investors own include Amarin (AMRN) , CRISPR Therapeutics (CRSP) , Vaxart (VXRT) , Nabriva Therapeutics (NBRV) , Novavax (NVAX) , VBI Vaccines (VBIV) , Aduro Biotech (ADRO) , Anavex Life Sciences (AVXL) , OpGen (OPGN) and

NASDAQ:ARDM

Aradigm (ARDM) Stock Price, News & Analysis

→ REVEALED: Elon Musk’s Secret A.I. Facility? (From InvestorPlace) (Ad)

Free ARDM Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.15
▼
$0.38
52-Week Range: N/A

Volume: N/A
Average Volume: 97,091 shs
Market Capitalization: $761,000.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Aradigm alerts:

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

About Aradigm Stock (NASDAQ:ARDM)

Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. Its lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and non-tuberculosis mycobacterium. The company is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis, and has tested for the prevention and treatment of inhaled bioterrorism infections, such as Coxiella burnetii or Q fever, inhalation anthrax, tularemia, melioidosis and pneumonic plague. Aradigm Corporation has collaboration agreements with Grifols, S.A. The company was founded in 1991 and is headquartered in Hayward, California.

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

ARDM Stock News Headlines

November 21, 2023 | investing.com

First International Bank of Israel Ltd (FIBI)

November 10, 2023 | investing.com

Altshuler Shaham Financial LTD (ALTF)

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

May 1, 2023 | marketwatch.com

Non-Cystic Fibrosis Bronchiectasis Market Forecast to 2030

April 22, 2023 | investing.com

Aerodrome Group Ltd (ARDM)

March 17, 2023 | finance.yahoo.com

Aerodrome Group Ltd (ARDM.TA)

December 28, 2022 | investopedia.com

How and Why Google Glass Failed

See More Headlines

Receive ARDM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aradigm and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2018
Today: 4/16/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Electromedical Equipment
Sub-Industry: N/A
Current Symbol: NASDAQ:ARDM
CUSIP: N/A
CIK: 1013238
Web: www.aradigm.com
Phone: 510-265-9000
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,700,000.00
Net Margins: -374.80%
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -374.15%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.23
Quick Ratio: 1.23

Sales & Book Value

Annual Sales: $14.47 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.83) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 15,220,000
Free Float: N/A
Market Cap: $761,000.00
Optionable: Optionable
Beta: 1.57

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Dr. John M. Siebert (Age 79)
Exec. Chairman, Interim Principal Exec. Officer & Acting Principal Financial Officer
Dr. Juergen Froehlich M.D. (Age 62)
MBA, FCPh, Chief Medical Officer
Dr. Igor Gonda (Age 71)
Consultant
Ms. Nancy E. Pecota (Age 59)
Consultant
Lisa Thomas
Corp. Controller

Key Competitors

View All Competitors

ARDM Stock Analysis - Frequently Asked Questions

How were Aradigm's earnings last quarter?: Aradigm Co. (NASDAQ:ARDM) released its quarterly earnings data on Thursday, November, 15th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.03. The firm had revenue of $0.28 million for the quarter.
What other stocks do shareholders of Aradigm own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aradigm investors own include Amarin (AMRN), CRISPR Therapeutics (CRSP), Vaxart (VXRT), Nabriva Therapeutics (NBRV), Novavax (NVAX), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Anavex Life Sciences (AVXL), OpGen (OPGN) and

This page (NASDAQ:ARDM) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Aradigm (ARDM) Stock Price, News & Analysis

About Aradigm Stock (NASDAQ:ARDM)

ARDM Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ARDM Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info